9781573314718

Foreword.

By J. CARL BARRETT

Introduction.

By YOON S. CHO-CHUNG, ALAN M. GEWTRTZ, AND CY A. STEIN

Part I. Antisense: Chemistry, Sequence Specificity, and Prodrug

Conceptual "Heat-Driven" Approach to the Synthesis of DNA Oligonucleotides on Microarrays.

(11)

By A. GRAJKOWSKI, J. CIESLAK, M.K. CHMTELEWSKI, V. MARCHÁN, L.R. PHILLIPS, A. WILK, AND S.L. BEAUCAGE

Reading, Writing, and Modulating Genetic Information with Boranophosphate Mimics of Nucleotides, DNA, and RNA.

(18)

By BARBARA RAMSAY SHAW, MIKHAIL DOBRIKOV, XIN WANG, DING WAN, KAIZHANG HE, JIN-LAI LIN, PING LI, VLADTMIR RAIT, ZINAIDA A. SERGUEEVA, AND DMITRI SERGUEEV

Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA.

(13)

By SUDHIR AGRAWAL AND EKAMBAR R. KANDIMALLA

Part II. Interference RNA and Gene Repair

The Effect of Hydroxyurea and Trichostatin A on Targeted Nucleotide Exchange in Yeast and Mammalian Cells.

(13)

By HETAL PAREKH-OLMEDO, JULIA U. ENGSTROM, AND ERIC B. KMIEC

Short Interfering RNA (siRNA)-Mediated RNA Interference (RNAi) in Human Cells.

(7)

By NATASHA J. CAPLEN AND SPYRO MOUSSES

RNA-Mediated Inhibition of HIV in a Gene Therapy Setting.

(9)

By ALESSANDRO MICHIENZI, DANIELA CASTANOTTO, NANCY LEE, SHIRLEY LI, JOHN A. ZAIA, AND JOHN J. ROSSI

Part III. Antisense Delivery and Gene Therapy

Therapeutic Potentialities of EWS-Fli-1 mRNA-Targeted Vectorized Anti-sense Oligonucleotides.

(6)

By A. MAKSIMENKO, G. LAMBERT, J.R. BERTRAND, E. FATTAL, P. COUVREUR, AND C. MALVY

HER-2-Targeted Antisense Oligonucleotide Results in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents.

(12)

By ANTONINA S. RAIT, KATHLEEN F. PIROLLO, DAVID ULICK, KEVIN CULLEN, AND ESTHER H. CHANG

Antisense to Apoptosis Inhibitors Facilitates Chemotherapy and TRAIL-Induced Death Signaling.

(5)

By UWE ZANGEMEISTER-WITTKE

Clusterin and IGFBPs as Antisense Targets in Prostate Cancer.

(10)

By MARTIN GLEAVE AND BURKHARD JANSEN

Part IV. CpG Immune Modulators

The Therapeutic Potential of Antigen-Oligonucleotide Conjugates.

105

(7)

By SANDIP K. DATTA, KENJI TAKABAYASHI, AND EYAL RAZ

Regulation of CpG-Induced Immune Activation by Suppressive Oligodeoxynucleotides.

112

(12)

By DENNIS M. KLINMAN, RAINALD ZEUNER, HIROSHI YAMADA, MAYDA GURSEL, DEBBIE CURRIE, AND IHSAN GURSEL

Part V. DNA Chips, Enhancer Decoys, Triple-Helix, Imaging Gene Expression, and Morpholino Antisense

CRE-Enhancer DNA Decoy: A Tumor Target Based Genetic Tool.

124

(10)

By YOON S. CHO-CHUNG

Antigene Radiotherapy: Targeted Radiodamage with 125I-Labeled Triplex-Forming Oligonucleotides.

134

(7)

By I.G. PANYUTIN, O.A. SEDELNIKOVA, V.N. KARAMYCHEV, AND R.D. NEUMANN

Gene Targeting by Triple Helix-Forming Oligonucleotides.

141

(13)

By ALOKES MAJUMDAR, NITIN PURI, NICHOLAS MCCOLLUM, SALLY RICHARDS, BERNARD CUENOUD, PAUL MILLER, AND MICHAEL M. SEIDMAN

Potent Inhibition of Hhal DNA Methylase by the Aglycon of 2-(1H)-Pyrimidinone Riboside (Zebularine) at the GCGC Recognition Domain.

154

(11)

By VICTOR E. MARQUEZ, RAMON ERITJA, JAMES A. KELLEY, DANA VANBEMMEL, AND JUDITH K. CHRISTMAN

Imaging Oncogene Expression.

165

(24)

By XIAOBING TIAN, MOHAN R. ARUVA, PONUGOTI S. RAO, WENYI QIN, PAUL READ, EDWARD R. SAUTER, MATHEW L. THAKUR, AND ERIC WICKSTROM

Custom Cancer Therapies: Safe and Effective Treatments for Most or All Cancers.

189

(8)

By JAMES E. SUMMERTON

Part VI. Antisense Targets and Combination Strategies

Antisense to the Early Growth Response-1 Gene (Egr-1) Inhibits Prostate Tumor Development in TRAMP Mice.

197

(20)

By VÉRONIQUE BARON, STEPHAN DUSS, JOHNG RHIM, AND DAN MERCOLA

Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides: In Vitro and in Vivo Activities and Mechanisms.

217

(19)

By HUI WANG, PATSY OLIVER, ZHUO ZHANG, SUDHIR AGRAWAL, AND RUIWEN ZHANG

Antisense Targeting Protein Kinase A Type I as a Drug for Integrated Strategies of Cancer Therapy.

236

(8)

By GIAMPAOLO TORTORA AND FORTUNATO CIARDIELLO

Part VII. Antisense Drug Development

Applying Antisense Technology: Affinitak™ and Other Antisense Oligonucleotides in Clinical Development.

244

(8)

By JON T. HOLMLUND

Clinical Studies in Patients with Solid Tumors Using a Second-Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I.

252

(11)

By S. MANI, S. GOEL, M. NESTEROVA, R.M. MARTIN, J.M. GRINDEL, M.L. ROTHENBERG, R. ZHANG, G. TORTORA, AND Y.S. CHO-CHUNG

Targeting Protein Kinase C-alpha (PKC-a) in Cancer with the Phosphorothioate Antisense Oligonucleotide Aprinocarsen.

263

(8)

By MICHAEL LAHN, KAREN SUNDELL, AND STEPHANIE MOORE

Closing Remarks.

271

(2)

By ALAN M. GEWIRTZ

Index of Contributors